CT
Citius Oncology, Inc.
CTOR · NASDAQ
$1.14 +10.68% (+$0.11)
1M +53.27%
Market Cap $94.8M
P/E Ratio -
Div. Yield -
ROE 102.98%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/B 2.35x
P/S 13.35x
PEG N/A
Growth
65 /100
Stable Book val. growth 7.35%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 277.34%
Op. margin 665.63%
Gross margin 53.13%
Quality
1 /100
Poor Asset turnover 0.06x
ROA 41.09%
ROIC 89.09%
Debt
51 /100
Moderate Current ratio 0.73x
Int. coverage -82.99x
Debt/Equity 0.25x
Stability
7 /100
Unstable EPS volatility 69.16%
Profitable years 0
Beta 3.53x
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre CTOR
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Leonard L. Mazur
Employees
285
Headquarters
Cranford
Evenimente viitoare
17 DEC.
Earnings
Upcoming earnings report